Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094237 | 1.00 | ACHE (0.47) | ACHETDP1GAAALDH1A1CA1 | |
| SCHEMBL280535 | 1.00 | ACHE (0.47) | ACHETDP1GAAALDH1A1CA1 | |
| SCHEMBL20661295 | 0.92 | ACHE (0.40) | ACHETDP1GAAALDH1A1CA1 | |
| SCHEMBL20661294 | 0.92 | ACHE (0.40) | ACHETDP1GAAALDH1A1CA1 | |
| SCHEMBL8779728 | 0.87 | — | — | |
| SCHEMBL17898104 | 0.86 | MLYCD (0.40) | ACHETDP1ALDH1A1TSHRLMNA | |
| SCHEMBL16841481 | 0.86 | TEAD4 (0.50) | ACHETDP1GAAALDH1A1TSHR | |
| SCHEMBL13772979 | 0.82 | CYP19A1 (0.48) | ACHETDP1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL28805138 | 0.79 | — | — | |
| SCHEMBL563967 | 0.79 | ACHE (0.50) | ACHETDP1GAAALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110477401-A | The purposes of sweet potato polypeptide compound | LANXI CHENMO BIOLOGICAL TECH CO LTD | 2019-11-22 | — | — | CN | disclosed |
| CN-110477400-A | A kind of preparation method of the polypeptide compound of pheretima preparation | LANXI CHENMO BIOLOGICAL TECH CO LTD | 2019-11-22 | — | — | CN | disclosed |
| CN-108034684-A | The preparation method of sweet potato polypeptide | 金华市铁骑士生物科技有限公司 | 2018-05-15 | — | — | CN | disclosed |
| US-20170349544-A1 | Ethynylbenzene Derivatives | DUKE UNIVERSITY | 2017-12-07 | — | — | US | disclosed |
| US-20170349544-A1 | Ethynylbenzene Derivatives | DUKE UNIVERSITY | 2017-12-07 | — | — | US | disclosed |
| US-9738604-B2 | Ethynylbenzene derivatives | DUKE UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738604-B2 | Ethynylbenzene derivatives | DUKE UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20130231323-A1 | ETHYNYLBENZENE DERIVATIVES | DUKE UNIVERSITY (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2012031298-A2 | ETHYNYLBENZENE DERIVATIVES | DUKE UNIVERSITY (US) | 2012-03-08 | — | — | WO | disclosed |
| US-7981318-B2 | Reaction reagent for trifluoromethylation | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2011-07-19 | — | — | US | disclosed |
| US-20100230633-A1 | Reaction Reagent for Trifluoromethylation | TOSOH F-TECH, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2080744-A1 | REACTION REAGENT FOR TRIFLUOROMETHYLATION | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-7166585-B2 | 24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3 | CYTOCHROMA INC. (CA) | 2007-01-23 | — | — | US | disclosed |
| US-20040132695-A1 | 24-Sulfur-substituted analogs of 1 alpha, 25-dihydroxy vitamin D3 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-07-08 | — | — | US | disclosed |
| WO-2002016570-A1 | DMS:ACCEPTOR OXIDOREDUCTASE | THE UNIVERSITY OF QUEENSLAND (AU) | 2002-02-28 | — | — | WO | disclosed |
| US-6218431-B1 | GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES | BAYER CORPORATION | 2001-04-17 | — | — | US | disclosed |
| EP-0934274-A1 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | Bayer Corporation (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998004528-A2 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | BAYER CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |
| US-5506256-A | PREVENTION AND/OR TREATMENT OF DEMENTIA, AMNESIA | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| EP-0468469-A2 | Proline derivatives | Japan Tobacco Inc. (JP) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132695-A1 | 24-Sulfur-substituted analogs of 1 alpha, 25-dihydroxy vitamin D3 | CYP24A1, CYP2R1, CYP27B1 | ACHE 4866/4885TDP1 4144/4885GAA 2423/4885 |
| US-20170349544-A1 | Ethynylbenzene Derivatives | Q6ZSR9, EPX, ZYX | ACHE 3065/4885TDP1 3187/4885GAA 1139/4885 |
| US-20130231323-A1 | ETHYNYLBENZENE DERIVATIVES | Q6ZSR9, EPX, ZYX | ACHE 3065/4885TDP1 3187/4885GAA 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.